Pitfalls of insulin-like growth factor I assays

Hormone Research

Volumn 71, Issue SUPPL. 1, 2009, Pages 30-33

  Bidlingmaier, Martin ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Binding proteins; Immunoassays; Interference; Reference ranges

Indexed keywords

BINDING PROTEIN; EPITOPE; GROWTH HORMONE; PEGVISOMANT; SOMATOMEDIN C;

ACROMEGALY; BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONFERENCE PAPER; DISEASE ACTIVITY; DRUG EFFICACY; GROWTH HORMONE DEFICIENCY; HUMAN; IMMUNOASSAY; LONG TERM CARE; PRIORITY JOURNAL;

DATA INTERPRETATION, STATISTICAL; DIAGNOSTIC TECHNIQUES, ENDOCRINE; HUMANS; IMMUNOASSAY; INDIVIDUALITY; INSULIN-LIKE GROWTH FACTOR I; OSMOLAR CONCENTRATION;

EID: 58549085582     PISSN: 03010163     EISSN: None     Source Type: Journal    
DOI: 10.1159/000178034     Document Type: Conference Paper

References (14)

1. Le Roith D, Bondy C, Yakar S, Liu JL, Butler A: The somatomedin hypothesis: 2001. Endocr Rev 2001;22:53-74.
2. Boisclair YR, Rhoads RP, Ueki I, Wang J, Ooi GT: The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. J Endocrinol 2001;170:63-70.
3. Clemmons DR: Commercial assays available for insulin-like growth factor I and their use in diagnosing growth hormone deficiency. Horm Res 2001;55:73-79.
4. Pokrajac-Simeunovic A, Trainer PJ: Pitfalls in the diagnosis of acromegaly. Horm Res 2004;62(suppl 3):74-78.
5. Ghigo E, Aimaretti G, Gianotti L, Bellone J, Arvat E, Camanni F: New approach to the diagnosis of growth hormone deficiency in adults. Eur J Endocrinol 1996;134:352-356.
6. Brabant G, von zur Muhlen A, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P: Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53-60.
7. Daughaday WH, Ward AP, Goldberg AC, Trivedi B, Kapadia M: Characterization of somatomedin binding in human serum by ultracentrifugation and gel filtration. J Clin Endocrinol Metab 1982;55:916-921.
8. Mohan S, Baylink DJ: Development of a simple valid method for the complete removal of insulin-like growth factor (IGF)-binding proteins from IGFs in human serum and other biological fluids: comparison with acid-ethanol treatment and C18 Sep-Pak separation. J Clin Endocrinol Metab 1995;80:637-647.
9. Blum WF, Breier BH: Radioimmunoassays for IGFs and IGFBPs. Growth Regul 1994;4(suppl 1):11-19.
10. Elmlinger MW, Kuhnel W, Weber MM, Ranke MB: Reference ranges for two automated chemiluminescent assays for serum insulinlike growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3). Clin Chem Lab Med 2004;42:654-664.
11. Chestnut RE, Quarmby V: Evaluation of total IGF-I assay methods using samples from type I and type II diabetic patients. J Immunol Methods 2002;259:11-24.
12. Quarmby V, Quan C, Ling V, Compton P, Canova-Davis E: How much insulin-like growth factor I (IGF-I) circulates? Impact of standardization on IGF-I assay accuracy. J Clin Endocrinol Metab 1998;83:1211-1216.
13. Massart C, Poirier JY: Serum insulin-like growth factor-I measurement in the follow-up of treated acromegaly: comparison of four immunoassays. Clin Chim Acta 2006;373:176-179.
14. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ: Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007;67:65-70.